HomeMost PopularInvestingWhy You Should Consider Adding Stryker (SYK) Stock to Your Investment Portfolio

Why You Should Consider Adding Stryker (SYK) Stock to Your Investment Portfolio

Actionable Trade Ideas

always free

Stryker Corporation (SYK) is poised for growth with its robust Mako robotic arm-assisted surgery platform and diversified product portfolio. Despite concerns about pricing pressure, shares of this Zacks Rank #2 (Buy) company have outperformed the industry, rising 16.3% year to date compared to a 2.7% decline in the industry.

Strykerโ€™s Growth Drivers

Stryker has seen strong demand for its Mako platform, which has unique features and has led to a healthy order book. Continued adoption, new launches, and software upgrades are expected to drive robust growth in Mako revenues in the second half of 2023. Stryker also benefits from its diversified product portfolio, protecting it against sales shortfalls during economic turmoil.

Stryker has a strong presence in robotics, artificial intelligence, and medical mechatronics, giving it an edge in the MedTech space. The companyโ€™s commitment to innovation and customer support positions it for growth as the effects of the pandemic subside. Recent product launches, such as the Q Guidance System for spine applications, have shown promising uptake. Cost-cutting initiatives are also in place to improve margins and mitigate inflationary pressure.

Challenges for Stryker

Exchange rate fluctuations and inflationary pressure are ongoing challenges for Stryker. Unfavorable currency rates have negatively impacted sales, and this trend is expected to continue. However, Strykerโ€™s overall positive outlook and growth prospects outweigh these challenges.

See also  Outrageously Successful Quarterly Performers Still UnderratedImagine the financial world as a battlefield, and last week's high-growth stock earnings as the victory cries of Elastic, Okta, and PVH. These gladiators of the market have shown invigorating strength and agility, proving their mettle against expectations and raising their banners high for all to see. Reaffirming their presence, these companies have not only exceeded earnings forecasts but propelled themselves toward monumental gains and prosperity. Let's delve into each of these triumphant warriors and celebrate their victories.Elastic: A Force to be Reckoned withElastic, the cloud analytics company, recently reported its second-quarter results, showcasing a growth so impressive it's practically unmissable. Surging past predictions, Elastic's Q2 earnings of $0.37 per share smashed the Zacks Consensus of $0.24 per share by a staggering 54%. The company has astoundingly surpassed the Zacks EPS Consensus for 20 consecutive quarters, exhibiting an astonishing average earnings surprise of 141% in its last four reports. With Q2 sales of $310.61 million, Elastic's stock has ascended by an incredible 115% this year. Forecasts for explosive growth in 2024 and 2025 further solidify its standing as a powerhouse in the market.Okta: A Formidable ContenderOkta Inc., a key player in enterprise identity solutions, shocked the market with its third-quarter earnings of $0.44 per share, outclassing expectations by 46%. Boasting an average earnings surprise of 30% over the last four quarters, Okta continues to outpace itself. With the stock surging 6% this year, the company's annual earnings are projected to leap from an adjusted loss in FY23 to $1.23 per share in FY24, with an even stronger outlook for FY25. The projected increase in total sales for FY24 and FY25 further enhance the allure of Okta's journey to profitability.PVH: A Veteran with Undeniable FortitudePVH Corporation, a stalwart in branded clothing and accessories, exhibited its enduring strength with Q3 earnings of $2.90 per share, surpassing expectations by 6%. Although sales were slightly below estimates, PVH is anticipated to witness consistent growth in annual earnings and total sales across FY24 and FY25. The company's 48% year-to-date surge, combined with its 9.5X forward earnings multiple, presents an enticing opportunity for investors.A Golden Opportunity for GrowthAt present, Elastic, Okta, and PVH hold a Zacks Rank #2 (Buy), cementing their position as robust assets for investors. The unyielding expansion and resilience showcased by these companies demand attention and recognition from all those seeking growth opportunities in the market. The dominance displayed by these triumphant entities is a clarion call for investors to take notice and consider their potential for colossal gains.Exciting News: Stock Set to Double in Months!

Estimate Trend

The Zacks Consensus Estimate for 2023 earnings per share is $10.37, indicating a year-over-year growth of 11%. Revenues are also expected to improve by 9.9% year over year, reaching $20.27 billion.

Other Stocks to Consider in the Medical Space

For a well-rounded investment portfolio in the medical sector, consider other top-ranked stocks like Align Technology (ALGN), HealthEquity, Inc. (HQY), and McKesson Corporation (MCK). These companies have strong growth potential and have outperformed the industry.

Note: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.